Navigation Links
WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy
Date:3/4/2008

re forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future d
'/>"/>
SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
3. Clinical Study Findings Show Safety and Procedure Success for TopSpin IntraVascular MRI Catheter for the Coronary Arteries
4. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
5. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
6. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
7. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. Vasogens Research Published in European Journal of Neuroscience
10. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
11. Newly Published EPA RCRA Method 6800 Supports AIT Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/29/2015)... -- According to a new market research report, ... (2015-2020), , published by Mordor Intelligence, the Global market is ... of 2020, with North America being ... the global market size. The Global market for Stem Cells ... the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) , ...
(Date:7/29/2015)...  AsureQuality and Ubiquitome have agreed to collaborate ... food and primary production sectors. The collaboration will ... the Freedom4. AsureQuality provides quality assurance ... shelf for producers, processors and Competent Authorities around ... control and pest management and surveillance programmes. ...
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Neuropathology services for VA and Military health systems 2
... Calif. , May 19 ChemoCentryx, Inc., ... the Company,s President and Chief Executive Officer is a ... Year® 2010 Award in Northern California .  According ... entrepreneurs who demonstrate extraordinary success in the areas of ...
... May 19 Hothead Technologies, Inc. and Sivix ... key computing fob and associated sensor monitoring module to ... are based upon the H.O.T.™ System, a patent-pending system ... of an athlete, firefighter, soldier, or other personnel and ...
... N.J. , May 19 Soligenix, Inc. ... late-stage biopharmaceutical company, announced today that the United States ... entitled "Treatment of Irritable Bowel Syndrome and Related Bowel ... (BDP) to treat irritable bowel syndrome (IBS), a painful ...
Cached Biology Technology:ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 2ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 3ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California 4Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 2Hothead Technologies Partners with Sivix Logistics to Add Customized Handheld Monitors and Autonomous Sensors to its Product Line 3Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate 2Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate 3Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate 4Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate 5Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate 6
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
(Date:7/2/2015)... , June 25, 2015 ... announced the addition of the "Natural Language ... Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... their offering. The key vendors occupying ... HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... for Species Exploration at Arizona State University names the Top ... list for 2009 was published to coincide with the 303rd ... It contains only two new plant species, one of which ... Linnean Society . Nepenthes attenboroughii , a ...
... green fluorescent protein known simply as GFP has revolutionized cell ... scientists to visualize proteins inside of cells and track them ... who discovered and developed the protein as a laboratory tool ... GFP as a fluorescent probe has one major drawback ...
... TU Delft and Molecular Imaging Labs (MI Labs) have ... into one piece of equipment. These techniques are particularly ... as microPET and microSPECT. SPECT and PET can be ... traditional microSPECT and microPET. The new device is known ...
Cached Biology News:Rare carnivorous plant on top 10 list of newly discovered species 2MIT chemists design new way to fluorescently label proteins 2TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
PFM8 Antibody...
Biology Products: